再生元制药公司宣布，其REMODEL临床试验的安全性数据与度普利尤单抗已知的安全性特征相符。试验结果显示，接受度普利尤单抗治疗的患者中不良事件发生率为62%。
这一数据进一步验证了该药物在临床使用中的安全性表现，为后续临床应用提供了重要参考依据。
再生元制药公司宣布，其REMODEL临床试验的安全性数据与度普利尤单抗已知的安全性特征相符。试验结果显示，接受度普利尤单抗治疗的患者中不良事件发生率为62%。
这一数据进一步验证了该药物在临床使用中的安全性表现，为后续临床应用提供了重要参考依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.